Duke CIVICs

 About Us

The Duke Human Vaccine Institute (DHVI) was selected to join the Collaborative Influenza Vaccine Innovation Centers (CIVICs) in all three components of the research program, which is funded by the National Institute of Allergic and Infectious Diseases (NIAID) through the Division of Microbiology and Infectious Diseases (DMID).

The CIVICs program aims to improve the durability of seasonal influenza vaccines and develop a universal influenza vaccine through iterative vaccine design, pre-clinical animal studies, and early phase clinical trials.

The Duke CIVICS program consists of multidisciplinary teams of investigators (Drs. Tony Moody, Gregory Sempowski, Matt Johnson, Georgia Tomaras, and Chip Walter) and their collaborators to support the research objectives laid out by the NIAID to design, manufacture, and test novel influenza vaccine candidates with the following attributes:

  • Be at least 75% effective against symptomatic influenza virus infection
  • Protect against group I and group II influenza A viruses
  • Provide durable protection that lasts at least one year and preferably through multiple influenza seasons
  • Be suitable for all age groups

Vaccine Design & Development

  • Vaccine Design
  • Immunological Analyses
  • Assay & Reagent Core

Vaccine Manufacturing

 

  • Vaccine & Trials Unit 
  • Challenge Unit
  • Biorepository

 

Vaccine Safety Studies

  • Good Manufacturing Facility (GMP)
  • Protein Production Facility (PPF)

CIVICS Network Map